These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 31786094)
1. Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target. Ikram S; Ahmad J; Durdagi S J Mol Graph Model; 2020 Mar; 95():107462. PubMed ID: 31786094 [TBL] [Abstract][Full Text] [Related]
2. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models. Zaka M; Abbasi BH; Durdagi S J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845 [TBL] [Abstract][Full Text] [Related]
3. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline. Zaka M; Abbasi BH; Durdagi S J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308 [TBL] [Abstract][Full Text] [Related]
4. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S Front Chem; 2020; 8():167. PubMed ID: 32328476 [TBL] [Abstract][Full Text] [Related]
5. Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease. Oktay L; Erdemoğlu E; Tolu İ; Yumak Y; Özcan A; Acar E; Büyükkiliç Ş; Olkan A; Durdaği S Turk J Biol; 2021; 45(4):459-468. PubMed ID: 34803447 [TBL] [Abstract][Full Text] [Related]
6. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models. Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122 [TBL] [Abstract][Full Text] [Related]
7. Physics-driven identification of clinically approved and investigation drugs against human neutrophil serine protease 4 (NSP4): A virtual drug repurposing study. Ahmad J; Ikram S; Hafeez AB; Durdagi S J Mol Graph Model; 2020 Dec; 101():107744. PubMed ID: 33032202 [TBL] [Abstract][Full Text] [Related]
8. Proposing Novel MAO-B Hit Inhibitors Using Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of Their Therapeutic Activity, Pharmacokinetic and Toxicity Properties. Is YS; Durdagi S; Aksoydan B; Yurtsever M ACS Chem Neurosci; 2018 Jul; 9(7):1768-1782. PubMed ID: 29671581 [TBL] [Abstract][Full Text] [Related]
9. Drug Re-positioning Studies for Novel HIV-1 Inhibitors Using Binary QSAR Models and Multi-target-driven In Silico Studies. Dogan B; Durdagi S Mol Inform; 2021 Feb; 40(2):e2000012. PubMed ID: 33405326 [TBL] [Abstract][Full Text] [Related]
10. Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays. Sahin K; Zengin Kurt B; Sonmez F; Durdagi S J Biomol Struct Dyn; 2020 Jul; 38(11):3342-3358. PubMed ID: 31462153 [TBL] [Abstract][Full Text] [Related]
11. Screening of small molecule libraries using combined text mining, ligand- and target-driven based approaches for identification of novel granzyme H inhibitors. Ikram S; Ahmad F; Ahmad J; Durdagi S J Mol Graph Model; 2021 Jun; 105():107876. PubMed ID: 33744783 [TBL] [Abstract][Full Text] [Related]
12. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. Chaudhari HK; Pahelkar A Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898 [TBL] [Abstract][Full Text] [Related]
13. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574 [TBL] [Abstract][Full Text] [Related]
14. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target. DurdaĞi S Turk J Biol; 2020; 44(3):185-191. PubMed ID: 32595355 [TBL] [Abstract][Full Text] [Related]
15. Drug repurposing against the RNA-dependent RNA polymerase domain of dengue serotype 3 by virtual screening and molecular dynamics simulations. Gangopadhyay A; Saha A J Biomol Struct Dyn; 2023 Jul; 41(11):5152-5165. PubMed ID: 35642087 [TBL] [Abstract][Full Text] [Related]
17. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
18. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors. Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831 [TBL] [Abstract][Full Text] [Related]
19. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations. Bharadwaj S; Dubey A; Kamboj NK; Sahoo AK; Kang SG; Yadava U Sci Rep; 2021 May; 11(1):10169. PubMed ID: 33986372 [TBL] [Abstract][Full Text] [Related]
20. Computer-assisted discovery of safe and effective DprE1/ aaRSs Inhibitors against TB utilizing Drug Repurposing approach. Imran M; Abida ; Alotaibi NM; Thabet HK; Alruwaili JA; Asdaq SMB; Eltaib L; Kamal M; Alshammari ABH; Alshammari AMA; Alshehri A J Infect Public Health; 2023 Apr; 16(4):554-572. PubMed ID: 36812878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]